Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study
BackgroundInhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) (referred to hereafter as anti-PD-(L)1 agents) are approved to treat a variety of advanced-stage cancers. Incorporating these agents into neoadjuvant/adjuvant treatme…